NEW YORK (GenomeWeb) – WaferGen Biosystems announced today that it has completed an offering of common stock and warrants that brought in gross proceeds of $20 million.

The offering comprises 2,000 units priced at $10,000 per unit. Each unit consists of 2,000 shares of common stock and 2,000 warrants to purchase shares of the firm's common stock. In total, 4 million shares of common stock and warrants to purchase 4 million shares were issued in the offering. The warrants have a term of five years and an exercise price of $5 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.